$0.49
9.49% yesterday
Nasdaq, May 20, 09:14 pm CET
ISIN
US65343E1082
Symbol
NXTC
Sector
Industry

NextCure, Inc. Stock price

$0.51
+0.14 37.78% 1M
-0.79 60.89% 6M
-0.26 34.06% YTD
-1.12 68.81% 1Y
-3.28 86.59% 3Y
-33.75 98.52% 5Y
-14.49 96.61% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.06 12.98%
ISIN
US65343E1082
Symbol
NXTC
Sector
Industry

Key metrics

Market capitalization $14.26m
Enterprise Value $-35.76m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.86
P/B ratio (TTM) P/B ratio 0.25
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-53.07m
Free Cash Flow (TTM) Free Cash Flow $-41.63m
Cash position $55.86m
EPS (TTM) EPS $-1.77
P/E forward negative
Short interest 0.67%
Show more

Is NextCure, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

NextCure, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a NextCure, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a NextCure, Inc. forecast:

Buy
100%

Financial data from NextCure, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 2.73 2.73
28% 28%
-
-2.73 -2.73
28% 28%
-
- Selling and Administrative Expenses 9.62 9.62
13% 13%
-
- Research and Development Expense 38 38
20% 20%
-
-50 -50
19% 19%
-
- Depreciation and Amortization 2.73 2.73
28% 28%
-
EBIT (Operating Income) EBIT -53 -53
20% 20%
-
Net Profit -50 -50
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about NextCure, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NextCure, Inc. Stock News

Neutral
GlobeNewsWire
19 days ago
Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 Plan to provide a proof of concept data readout in the first half of 2026 Cash of approximately $55.9 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., May 01, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a cli...
Neutral
GlobeNewsWire
about 2 months ago
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET.
Neutral
GlobeNewsWire
3 months ago
BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2024 financial results.
More NextCure, Inc. News

Company Profile

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Head office United States
CEO Michael Richman
Employees 43
Founded 2015
Website www.nextcure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today